ZIMMER BIOMET HOLDINGS, INC. (ZBH) /
The cash flow of ZIMMER BIOMET HOLDINGS, INC. over the past 10 years
Chart ZIMMER BIOMET HOLDINGS, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, ZIMMER BIOMET HOLDINGS, INC.'s operating cash flow was $1.7B and its capital expenditures $224.5M, leaving free cash flow of $1.47B. Free cash flow was above zero in all 10 years shown. It ranged from $963.7M in fiscal 2020 to $1.58B in fiscal 2018. Capital expenditures were highest in fiscal 2023, at $291.1M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $1.7B | $224.5M | $1.47B |
| 2024ended Dec 31, 2024 | $1.5B | $203.8M | $1.3B |
| 2023ended Dec 31, 2023 | $1.58B | $291.1M | $1.29B |
| 2022ended Dec 31, 2022 | $1.36B | $187.9M | $1.17B |
| 2021ended Dec 31, 2021 | $1.4B | $143.6M | $1.26B |
| 2020ended Dec 31, 2020 | $1.08B | $111.9M | $963.7M |
| 2019ended Dec 31, 2019 | $1.59B | $207.1M | $1.38B |
| 2018ended Dec 31, 2018 | $1.75B | $162.7M | $1.58B |
| 2017ended Dec 31, 2017 | $1.58B | $156M | $1.43B |
| 2016ended Dec 31, 2016 | $1.63B | $184.7M | $1.45B |
Fiscal years as ZIMMER BIOMET HOLDINGS, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on ZIMMER BIOMET HOLDINGS, INC.
- The revenue of ZIMMER BIOMET HOLDINGS, INC.
- The profitability of ZIMMER BIOMET HOLDINGS, INC.
- The debt of ZIMMER BIOMET HOLDINGS, INC.
- The dividends of ZIMMER BIOMET HOLDINGS, INC.
- All of ZIMMER BIOMET HOLDINGS, INC.'s financials, charted
Companies of a similar size
- TSEMTOWER SEMICONDUCTOR LTD.
- MEDPMedpace Holdings, Inc.
- TOSTToast, Inc.
- FTVFortive Corporation
- RGLDRoyal Gold, Inc
Not investment advice. This page shows what ZIMMER BIOMET HOLDINGS, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.